StockStory4d agoneutral
Halozyme Therapeutics Earnings: What To Look For From HALOBiopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) will be announcing earnings results this Monday after market close. Here’s what to expect.
Actualités
Uniquement les titres à fort signal — événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
53last 24h
1680last 7d
314🟢 bullish (7d)
170🔴 bearish (7d)
136publishers
GuruFocus.com5d agoneutral
Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...Halozyme Therapeutics Inc (HALO) reports a 42% revenue surge, unveils a $1 billion share buyback, and outlines ambitious growth plans for 2026.
MarketBeat5d agoneutral
Halozyme Therapeutics Q1 Earnings Call HighlightsHalozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization. On the company’s earnings call, President and CEO
Zacks6d agoneutral
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to SayWhile the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks6d agoneutral
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue EstimatesHalozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks9d agobullish
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue EstimatesANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks10d agobullish
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue EstimatesImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks11d agoneutral
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance MeasuresBesides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
MarketBeat11d agoneutral
Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 GuidanceHalozyme Therapeutics (NASDAQ:HALO) stockholders elected two Class I directors and approved several governance items at the company’s annual meeting, while President and CEO Helen Torley highlighted 2025 execution, recent acquisitions, new commercial agreements, and updated financial guidance. Stoc
Zacks17d agobullish
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks19d agoneutral
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseHalozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.